Thursday, February 2, 2023
HomeHealthCipla gets drug regulator's nod to market Molnupiravir for Covid treatment

Cipla gets drug regulator’s nod to market Molnupiravir for Covid treatment

Earlier in the year, Cipla entered into a licensing agreement with Merck Sharpe Dohme to make and supply Molnupiravir in India and to over 100 low and middle-income countries.

Text Size:

New Delhi: Drug major Cipla on Tuesday said it has received emergency use authorisation (EUA) permission from the Drug Controller General of India (DCGI) to launch antiviral drug Molnupiravir in the country to treat mild-to-moderate COVID-19.

The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu.

“This launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients,” Cipla MD and Global CEO Umang Vohra said in a statement.

Earlier during the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs).

The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies.

Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.

Molnupiravir inhibits the replication of multiple RNA viruses including SARS-CoV-2.

Cipla said it will soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID treatment centers across the country.

The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India, it added.

This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.


Also read: Hyderabad open for New Year celebrations amid Omicron scare, thanks to ‘loose’ govt order


 

Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular